Exploring the novel functions of cyclin DS in T cells and tumor progression

Active Grant Awarded

Award ID
R01CA298320
Recipient
Awarding agency
Obligated
$643,053

Award facts

Assistance listing
93.396 Cancer Biology Research
Completion date 11% complete
Place of performance
Charleston, SC 29425, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health National Cancer Institute, awarded The Medical University of South Carolina $643,053 on April 24, 2026, under Assistance Listing 93.396, Cancer Biology Research, for grant R01CA298320. The grant funds research into the kinase-independent functions of cyclin D3 in T cells, with Aim 1 determining how cyclin D3 downregulates intracellular cholesterol to reduce T-cell survival and Aim 2 determining how it suppresses adhesion protein expression to inhibit T-cell tumor infiltration. The work targets T-cell immunotherapy against solid tumors. The National Cancer Institute obligated the full $643,053, and performance runs through April 30, 2031, at Charleston, South Carolina 29425.

Loyola University Chicago's Health Sciences Campus serves as sub-recipient under sub-award R01CA298320-A26-0378-S001, dated August 20, 2026. Under that sub-award, Dr. Nishimura builds retroviral and lentiviral vectors, uses them to genetically modify mouse and human T cells, assesses T-cell function in vitro, and supplies large numbers of the modified cells for in vivo tumor studies.

The parent program supports fundamental research on the cause and nature of cancer, with the expectation of better methods for its prevention, detection, diagnosis, and treatment.

Description

Abstract
Poor T-cell tumor trafficking/infiltration and low T-cell survival in the harsh tumor microenvironment (TME) are two critical challenges for the success of T-cell-based immunotherapy against solid tumors. Thus, determining the novel intrinsic mechanism(S) that regulate T-cell infiltration and survival is critical to developing efficient immunotherapy strategies for treating solid tumors. D-type cyclins (D1, D2, and D3) bind cyclin-dependent kinases 4 and 6 (CDK4/6), and the activity of cyclin D/CDK complexes promotes entry into the cell cycle. Cyclin DS carry out CDK4/6 kinase-dependent and kinase-independent functions. T cells primarily express cyclin D2 and D3. The CDK4/6 kinase-dependent functions of cyclin DS in T cells were recently reported, but their kinase- independent functions in T cells are not well defined. This study revealed that cyclin D3 deletion in T cells suppressed colorectal tumor growth. Our data indicates that the increased T-cell survival and T-cell tumor infiltration of D3-deleted T cells is due to its kinase-independent function. Intracellular cholesterol sufficient prevents T-cell apoptosis in the harsh solid tumor microenvironment. RNA-SEQ analysis showed that genes functioning in cholesterol homeostasis were upregulated in D3-deleted T cells. In vitro studies showed that kinase-independent cyclin D3 decreased pparg expression, which dominates the expression of genes controlling intracellular cholesterol levels. Thus, aim 1 will determine the mechanism of how cyclin D3 downregulates intracellular cholesterol levels to decrease T-cell survival, promoting colon cancer progression. Meanwhile, adhesion proteins are critical in T-cell tumor infiltration. Aim 2 will determine the kinase-independent function of cyclin D3 in suppressing adhesion protein expression to inhibit T-cell tumor infiltration. Of note, our study showed that cyclin D2 overexpression decreased the expression of cyclin D3, augmenting T-cell capacity to kill tumor cells. Aim 3 will in vivo evaluate the therapeutic efficacy of cyclin D manipulated adoptive T cells on melanoma and colon cancers. We will manipulate cyclin DS expression in T cells to assess the anti-solid tumor efficacy of adoptive T-cell therapy. Our overarching hypothesis is that manipulating cyclin D expression in T cells augments solid tumor immunotherapy efficacy by increasing T-cell tumor infiltration and T-cell survival through their kinase-independent functions.

Subawards

Subrecipient Amount Awarded
Loyola University Of Chicago The role of Dr. Nishimura in this proposal will be to use his experience in making retroviral and lentiviral vectors and using them to transduce mouse and human… $217,667

Quick answers

Who received award R01CA298320?

R01CA298320 was awarded to The Medical University Of South Carolina by National Cancer Institute (National Institutes of Health) on April 24, 2026.

How much is award R01CA298320 worth?

$643,053 has been obligated on R01CA298320.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award